Metagenomi, Inc. (NASDAQ:MGX) Receives $10.00 Average PT from Analysts

Metagenomi, Inc. (NASDAQ:MGX) has received a consensus rating of “Moderate Buy” from the five brokerages that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $10.00.

A number of equities analysts recently issued reports on MGX shares. Wall Street Zen raised shares of Metagenomi from a “sell” rating to a “hold” rating in a research note on Saturday, October 25th. Zacks Research raised Metagenomi from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 17th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Metagenomi in a report on Monday, December 22nd.

Metagenomi Price Performance

MGX stock opened at $1.77 on Friday. The firm has a 50 day simple moving average of $1.79 and a two-hundred day simple moving average of $2.05. The stock has a market cap of $66.43 million, a PE ratio of -0.74 and a beta of 0.50. Metagenomi has a one year low of $1.23 and a one year high of $4.00.

Metagenomi (NASDAQ:MGX) last released its earnings results on Wednesday, November 12th. The company reported ($0.55) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.05. The company had revenue of $8.66 million during the quarter, compared to the consensus estimate of $7.82 million. Metagenomi had a negative return on equity of 43.19% and a negative net margin of 287.06%. On average, research analysts expect that Metagenomi will post -2.46 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. BNP Paribas Financial Markets increased its position in shares of Metagenomi by 1,840.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 15,171 shares of the company’s stock valued at $36,000 after purchasing an additional 14,389 shares during the last quarter. Bank of America Corp DE lifted its holdings in Metagenomi by 508.5% during the third quarter. Bank of America Corp DE now owns 18,766 shares of the company’s stock valued at $44,000 after purchasing an additional 15,682 shares in the last quarter. Vanguard Personalized Indexing Management LLC boosted its position in shares of Metagenomi by 53.1% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 21,515 shares of the company’s stock worth $32,000 after purchasing an additional 7,458 shares during the period. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Metagenomi in the third quarter worth $64,000. Finally, Man Group plc bought a new stake in shares of Metagenomi during the 3rd quarter valued at $125,000.

Metagenomi Company Profile

Metagenomi, Inc (NASDAQ: MGX) is a biotechnology company that specializes in the discovery and engineering of novel proteins and enzymes using metagenomics and CRISPR-based genome editing. The company’s proprietary platform integrates vast environmental DNA libraries with advanced machine learning and high-throughput screening to identify, optimize and commercialize enzymes for industrial, agricultural and pharmaceutical applications. By tapping into genetic diversity found in nature, Metagenomi aims to accelerate the development of tailored biocatalysts that improve process efficiency, reduce costs and support sustainability initiatives.

Metagenomi’s technology offerings include custom enzyme discovery services, protein engineering tools and licensing of optimized biocatalysts to partners across multiple sectors.